Capricor Therapeutics Valuation
| CAPR Stock | USD 23.09 1.20 5.48% |
At this time, the firm appears to be undervalued. Capricor Therapeutics shows a prevailing Real Value of $28.87 per share. The current price of the firm is $23.09. Our model approximates the value of Capricor Therapeutics from analyzing the firm fundamentals such as Shares Outstanding of 54.4 M, operating margin of (7.79) %, and Return On Equity of -1.08 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Capricor Therapeutics' valuation include:
Price Book 14.1986 | Enterprise Value | Enterprise Value Ebitda (2.73) | Price Sales 106.9852 | Enterprise Value Revenue 99.4363 |
Undervalued
Today
Please note that Capricor Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Capricor Therapeutics is based on 3 months time horizon. Increasing Capricor Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Capricor stock is determined by what a typical buyer is willing to pay for full or partial control of Capricor Therapeutics. Since Capricor Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Capricor Stock. However, Capricor Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 23.09 | Real 28.87 | Target 50.8 | Hype 27.0 | Naive 22.81 |
The intrinsic value of Capricor Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Capricor Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Capricor Therapeutics helps investors to forecast how Capricor stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Capricor Therapeutics more accurately as focusing exclusively on Capricor Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Capricor Therapeutics' intrinsic value based on its ongoing forecasts of Capricor Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Capricor Therapeutics' closest peers.
Capricor Therapeutics Cash |
|
Capricor Therapeutics Total Value Analysis
Capricor Therapeutics is currently projected to have valuation of 1.15 B with market capitalization of 1.19 B, debt of 1.45 M, and cash on hands of 51.42 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Capricor Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.15 B | 1.19 B | 1.45 M | 51.42 M |
Capricor Therapeutics Investor Information
About 17.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.75. Capricor Therapeutics last dividend was issued on the 5th of June 2019. The entity had 1:10 split on the 5th of June 2019. Based on the key indicators related to Capricor Therapeutics' liquidity, profitability, solvency, and operating efficiency, Capricor Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Capricor Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Capricor Therapeutics has an asset utilization ratio of 13.06 percent. This connotes that the Company is making $0.13 for each dollar of assets. An increasing asset utilization means that Capricor Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Capricor Therapeutics Profitability Analysis
Based on Capricor Therapeutics' profitability indicators, Capricor Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Capricor Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2001-03-31 | Previous Quarter -25.9 M | Current Value -24.6 M | Quarterly Volatility 4.9 M |
For Capricor Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Capricor Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Capricor Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Capricor Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Capricor Therapeutics over time as well as its relative position and ranking within its peers.
Capricor Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Capricor Therapeutics is estimated to be 0.03785 with future projections ranging from a low of -0.59 to a high of 0.7725. Capricor Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.75. Please be aware that the consensus of earnings estimates for Capricor Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Capricor Therapeutics Earnings Estimation Breakdown
The calculation of Capricor Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Capricor Therapeutics is estimated to be 0.03785 with the future projection ranging from a low of -0.59 to a high of 0.7725. Please be aware that this consensus of annual earnings estimates for Capricor Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.59 Lowest | Expected EPS | 0.77 Highest |
Capricor Therapeutics Earnings Projection Consensus
Suppose the current estimates of Capricor Therapeutics' value are higher than the current market price of the Capricor Therapeutics stock. In this case, investors may conclude that Capricor Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Capricor Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 10 | 73.85% | 0.0 | 0.03785 | -1.75 |
Capricor Therapeutics Ownership Allocation
Capricor Therapeutics holds a total of 54.4 Million outstanding shares. 30% of Capricor Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Capricor Therapeutics Profitability Analysis
The company reported the previous year's revenue of 22.27 M. Net Loss for the year was (40.47 M) with loss before overhead, payroll, taxes, and interest of (64.75 M).About Capricor Therapeutics Valuation
The stock valuation mechanism determines Capricor Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Capricor Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Capricor Therapeutics. We calculate exposure to Capricor Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Capricor Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -24.9 M | -23.7 M | |
| Pretax Profit Margin | (2.09) | (2.19) | |
| Operating Profit Margin | (2.20) | (2.31) | |
| Net Loss | (2.09) | (2.19) | |
| Gross Profit Margin | (1.43) | (1.50) |
Capricor Therapeutics Current Valuation Indicators
Capricor Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Capricor Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Capricor Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Capricor Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Capricor Therapeutics' worth.Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.